Ultragenyx at the Goldman Sachs Global Healthcare Conference
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a pioneering biopharmaceutical company, is set to make a notable appearance at the prestigious Goldman Sachs 46th Annual Global Healthcare Conference. On Tuesday, June 10, 2025, at 10:00 a.m. ET, Emil Kakkis, M.D., Ph.D., who serves as the company’s chief executive officer, will engage in an insightful discussion during a fireside chat at the event.
What to Expect from the Event
This conference is an excellent platform for Ultragenyx to showcase its innovative approaches in developing groundbreaking therapies for serious rare and ultra-rare genetic diseases. The event attracts significant attention from investors, analysts, and healthcare professionals, making it an ideal opportunity for the company to highlight its recent advancements and commitment to transforming patient care.
Live and Archived Webcast
For those interested in tuning in, a live webcast of the panel discussion will be available, along with an archived version on the company’s official website. This accessibility ensures that anyone interested in Ultragenyx’s strategic vision and therapeutic developments can engage with the content, even if they are unable to attend the event in real-time.
Understanding Ultragenyx's Mission
Ultragenyx is at the forefront of the biopharmaceutical industry, focusing on the development and commercialization of novel therapies that address unmet medical needs. Their pipeline consists of promising therapies aimed at severe genetic conditions for which conventional treatment options are often unavailable. This commitment to innovation is crucial, as many patients with rare diseases are often left with few alternatives.
Diverse Portfolio of Therapies
The company has built a robust portfolio filled with both approved treatments and product candidates, reflecting their strategic approach to drug development. Ultragenyx aims to address diseases with high unmet medical need and establish clear biological pathways for potential therapies. This dedication ensures that their development efforts are aligned with patient needs, ultimately leading to more effective treatment solutions.
Experienced Leadership at the Helm
Ultragenyx is led by a seasoned management team that possesses extensive expertise in the development and commercialization of therapeutics for rare diseases. Their strategy emphasizes a time- and cost-efficient approach to drug development, ensuring that they can bring safe and effective therapies to patients as swiftly as possible.
Commitment to Patient Care
The urgency with which Ultragenyx operates reflects their commitment to patient care and the pressing need for effective treatments in the rare disease space. By focusing on both innovation and efficiency, the company positions itself as a leader in the biopharmaceutical field, dedicated to making a significant impact in the lives of patients facing rare and challenging health conditions.
Contact Information
For investors seeking further information regarding Ultragenyx, the company encourages inquiries. Joshua Higa from the investor relations team is available to provide insights and answer questions. Interested parties can reach out via email at ir@ultragenyx.com.
Frequently Asked Questions
1. What type of company is Ultragenyx Pharmaceutical?
Ultragenyx is a biopharmaceutical company focused on developing therapies for rare and ultra-rare genetic diseases.
2. Who is participating in the Goldman Sachs conference?
Emil Kakkis, M.D., Ph.D., the CEO of Ultragenyx, will be participating in the event.
3. Where can I access the event's webcast?
The webcast can be accessed through Ultragenyx's official website during and after the conference.
4. What is the mission of Ultragenyx?
The mission of Ultragenyx is to provide innovative treatments for patients with serious rare and ultra-rare genetic diseases.
5. How can investors contact Ultragenyx for more information?
Investors can contact Joshua Higa via email at ir@ultragenyx.com for inquiries.
